Technical Analysis for EARS - Auris Medical Holding AG

Grade Last Price % Change Price Change
grade F 0.999 -3.01% -0.03
EARS closed down 3.01 percent on Friday, May 29, 2020, on 48 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical EARS trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
MACD Bearish Signal Line Cross Bearish -3.01%
20 DMA Support Bullish -3.01%
1,2,3 Pullback Bullish Bullish Swing Setup -3.01%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.01%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical trials for treating acute inner ear tinnitus. The company is also developing AM-111 for the treatment of acute sensorineural hearing loss, as well as for Meniere diseases; and other development programs comprising AM-102 and AM-123 that are in preclinical studies. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, and drug delivery devices and formulations for the treatment of inner ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Biopharmaceutical Pharmaceutical Products Drug Delivery Nervous System Perception Hearing Loss Auditory System Drug Delivery Devices Ear Hearing Sensorineural Hearing Loss Tinnitus

Is EARS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.2
52 Week Low 0.65
Average Volume 238,986
200-Day Moving Average 1.58
50-Day Moving Average 0.90
20-Day Moving Average 1.02
10-Day Moving Average 1.07
Average True Range 0.12
ADX 35.44
+DI 29.05
-DI 12.74
Chandelier Exit (Long, 3 ATRs ) 1.03
Chandelier Exit (Short, 3 ATRs ) 1.15
Upper Bollinger Band 1.15
Lower Bollinger Band 0.89
Percent B (%b) 0.41
BandWidth 25.01
MACD Line 0.03
MACD Signal Line 0.04
MACD Histogram -0.007
Fundamentals Value
Market Cap 44.28 Million
Num Shares 44.3 Million
EPS -0.75
Price-to-Earnings (P/E) Ratio -1.33
Price-to-Sales 0.00
Price-to-Book 6.14
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.08
Resistance 3 (R3) 1.08 1.06 1.07
Resistance 2 (R2) 1.06 1.04 1.06 1.06
Resistance 1 (R1) 1.03 1.02 1.01 1.03 1.06
Pivot Point 1.00 1.00 0.99 1.00 1.00
Support 1 (S1) 0.97 0.98 0.96 0.97 0.94
Support 2 (S2) 0.95 0.97 0.95 0.93
Support 3 (S3) 0.92 0.95 0.93
Support 4 (S4) 0.92